Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRB2 | P62993 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | NTSR2 | O95665 | 4/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.42 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 3/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30131170 | 0.95 | GRB2 (0.47) | GRB2F2ACENTSR2NTSR1 | |
| SCHEMBL31433252 | 0.93 | GRB2 (0.50) | GRB2F2ACENTSR2NTSR1 | |
| SCHEMBL29462926 | 0.89 | GRB2 (0.54) | GRB2F2ACENTSR2NTSR1 | |
| SCHEMBL31433231 | 0.89 | FNTA (0.47) | GRB2FNTAFNTBXIAPDPP3 | |
| SCHEMBL30772337 | 0.89 | GRB2 (0.54) | GRB2F2ACENTSR2NTSR1 | |
| SCHEMBL31433348 | 0.88 | CALCR (0.45) | GRB2NTSR2NTSR1SORT1 | |
| SCHEMBL31433333 | 0.87 | CALCR (0.46) | NTSR2NTSR1SORT1 | |
| SCHEMBL31232442 | 0.86 | GRB2 (0.51) | GRB2F2NTSR2NTSR1SORT1 | |
| SCHEMBL30239685 | 0.86 | XIAP (0.47) | GRB2F2NTSR2NTSR1SORT1 | |
| SCHEMBL31433173 | 0.85 | ACE (0.44) | GRB2F2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | CALICO LIFE SCIENCES LLC (US) | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074942-A1 | COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E | MICA, CD74, HLA-DRB1 | GRB2 843/4885F2 2732/4885ACE 2383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.